Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
2.010
+0.010 (0.50%)
Jul 25, 2025, 1:13 PM - Market open
Outlook Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Outlook Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $9.6, which forecasts a 377.61% increase in the stock price over the next year. The lowest target is $3 and the highest is $21.
Price Target: $9.6 (+377.61%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 6, 2025.
Analyst Ratings
The average analyst rating for Outlook Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $24 → $21 | Strong Buy | Maintains | $24 → $21 | +944.78% | Jun 6, 2025 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $33 → $24 | Strong Buy | Maintains | $33 → $24 | +1,094.03% | Feb 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $3 | Strong Buy | Maintains | $30 → $3 | +49.25% | Feb 18, 2025 |
| Chardan Capital | Chardan Capital | Hold Maintains $3 | Hold | Maintains | $3 | +49.25% | Feb 18, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +497.01% | Jan 17, 2025 |
Financial Forecast
Revenue This Year
6.08M
Revenue Next Year
31.54M
from 6.08M
Increased by 419.06%
EPS This Year
-1.10
from -4.06
EPS Next Year
-1.13
from -1.10
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 9.1M | 50.4M | 136.5M | ||
| Avg | 6.1M | 31.5M | 125.5M | ||
| Low | 1.7M | 16.8M | 113.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 729.4% | 332.7% | ||
| Avg | - | 419.1% | 298.0% | ||
| Low | - | 175.8% | 260.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.76 | -1.00 | 0.97 | ||
| Avg | -1.10 | -1.13 | 0.79 | ||
| Low | -1.41 | -1.18 | 0.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.